J&J's Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Barcelona – The tyrosine kinase 2 (TYK2) inhibitor deucravacitinib significantly reduced disease activity in adult patients with active psoriatic arthritis (PsA) in the Phase III POETYK PsA-1 study. The drug improved both musculoskeletal and cutaneous manifestations, as well as quality of life, with overall good...
Two new indications of Tremfya (guselkumab) approved for the treatment of Inflammatory Bowel Disease
Tremfya is the first and only fully-human, dual-acting IL-23p19 subunit inhibitor approved in both ulcerative colitis and Crohn’s disease The post Two new indications of Tremfya (guselkumab) approved for the treatment of Inflammatory Bowel Disease appeared first on Irish Medical Times.
J&J's Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial
Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis (PsA).The post J&J’s Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial appeared first on Clinical Trials Arena.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
